Ercole Biotech, INC.;Roche Innovation Center Copenhagen A/S
发明人:
申请号：
EP07821575.3
公开号：
EP2147103B1
申请日:
2007.10.19
申请国别(地区):
EP
年份:
2018
代理人:
摘要：
The present invention relates to splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has thereputic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH.
